Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Pig influenza vaccine study shows promising results
“To our knowledge this is the first evidence in a large animal that T cell responses in the lung induced by aerosol immunisation are protective” – Elma Tchlian.
Researchers used aerosol immunisation to induce T-cell responses.

Scientists at The Pirbright Institute and the University of Oxford have made what they call a “significant advance” in developing the next generation of influenza vaccines.

In a new study, the researchers immunised by aerosol pigs which had been pre-exposed to the pH1N1 strain of influenza with viral vectored vaccines (ChAdOx2 and MVA) that expressed the influenza matrix protein (M1) and nucleoprotein (NP).

By focusing on activating T-cells, rather than solely focusing on antibodies, the team hoped that the immune system would be able to respond to a greater variety of viruses.

Currently, influenza vaccines target specific strains. Finding a way to create a universal influenza vaccine that protects against multiple strains would do away with the need for a new vaccine each year as new variants emerge.

When the pigs were exposed to the H3N2 strain four weeks later, the researchers found that all three immunisations (M1, NP, and NPM1) reduced lung pathology M1 offered the greatest protection.

NP and NPM1 immunisation induced both T-cell and antibody responses, while M1 immunisation induced T-cell responses but no antibodies.

The researchers believe the breakthrough could pave the way for advances in creating the next-generation of influenza vaccines that offer protection against multiple strains.  

Dame Sarah Gilbert, professor of vaccinology at the Pandemic Sciences Institute, University of Oxford, said: “To our knowledge this is the first evidence in a large animal that T cell responses in the lung induced by aerosol immunisation are protective.

“We believe that these results are a significant advance and highly relevant to the development of next generation vaccines for influenza and other respiratory pathogens.”

Elma Tchlian, head of Pirbright’s Mucosal Immunology Group, added “This study shows the importance of targeting the respiratory tract through aerosol administration to induce local immunity and prevent severe disease.

“This approach has significant implications for both human and veterinary medicine and highlights the potential of respiratory vaccines for influenza and other respiratory pathogens.”

The study has been published in the journal NPJ Vaccines.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.